Analytical Data
-
Gene name
HSD3B1
- Application
-
Alternative Names
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type I
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P14060
-
Expression Region
2-237aa
-
Molecular Weight
33.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HSD3B1 (3-beta-hydroxysteroid dehydrogenase type 1) recombinant protein is grounded in its essential role in steroidogenesis, which is critical for the biosynthesis of steroid hormones in various tissues, including the adrenal glands, gonads, and placenta. HSD3B1 catalyzes the conversion of pregnenolone to progesterone, playing a pivotal role in the steroid hormone production pathway. Disruptions or mutations in the HSD3B1 gene can lead to significant hormonal imbalances associated with various health disorders, such as adrenal insufficiency and reproductive dysfunction. Recent advances in recombinant protein technologies have enabled the production of HSD3B1 in heterologous systems, facilitating its purification and functional characterization. This research is crucial for understanding the enzyme’s biochemical properties, regulatory mechanisms, and its implications in diseases. Additionally, the development of HSD3B1 inhibitors or activators holds potential therapeutic applications in treating conditions like hormone-sensitive cancers and disorders of steroid metabolism. Overall, the exploration of HSD3B1 recombinant protein serves as a foundational avenue for advancing our knowledge of endocrine regulation and potential clinical interventions.
